JAMA[journal] 检索结果

5041. Cost-effective Global Strep B Vaccination Would Prevent Infant Deaths.

作者: Emily Harris.
来源: JAMA. 2023年329卷14期1143页

5042. FDA Updates Breast Density Reporting Standards, Other Mammogram Rules.

作者: Emily Harris.
来源: JAMA. 2023年329卷14期1142-1143页

5043. Systematic Review: What Works to Prevent Falls for Older People.

作者: Emily Harris.
来源: JAMA. 2023年329卷14期1142页

5044. Incomplete Information in Table.

来源: JAMA. 2023年329卷11期943页

5045. Noah Webster as Epidemiologist.

来源: JAMA. 2023年329卷11期945页

5046. Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone.

作者: Amani Meaidi.;Christian Torp-Pedersen.;Øjvind Lidegaard.;Lina Steinrud Mørch.
来源: JAMA. 2023年329卷11期935-937页

5047. Prevalence and County-Level Distribution of Births in Catholic Hospitals in the US in 2020.

作者: Alice F Cartwright.;Brooke W Bullington.;Kavita Shah Arora.;Jonas J Swartz.
来源: JAMA. 2023年329卷11期937-939页

5048. Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease.

作者: Nirvik Pal.;Miklos D Kertai.;Mark Nelson.
来源: JAMA. 2023年329卷11期939页

5049. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons.

作者: Sarah Glynne.;Louise Newson.;Dan Reisel.
来源: JAMA. 2023年329卷11期940-941页

5050. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons.

作者: Margaret Nachtigall.;Richard Nachtigall.;Lila Nachtigall.
来源: JAMA. 2023年329卷11期940页

5051. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons.

作者: Rowan T Chlebowski.;Aaron K Aragaki.
来源: JAMA. 2023年329卷11期942页

5052. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons.

作者: Garnet L Anderson.
来源: JAMA. 2023年329卷11期941页

5053. Preoperative Hemodialysis Timing and Postoperative Mortality in Patients With End-stage Kidney Disease-Reply.

作者: Vikram Fielding-Singh.;Matthew W Vanneman.;Eugene Lin.
来源: JAMA. 2023年329卷11期939-940页

5054. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons-Reply.

作者: Gerald Gartlehner.;Leila Kahwati.
来源: JAMA. 2023年329卷11期943页

5055. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons-Reply.

作者: Carol M Mangione.;Wanda Nicholson.;James Stevermer.
来源: JAMA. 2023年329卷11期942-943页

5056. Early vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial.

作者: Sarah Averbach.;Gennifer Kully.;Erica Hinz.;Arnab Dey.;Holly Berkley.;Marisa Hildebrand.;Florin Vaida.;Sadia Haider.;Lisa G Hofler.
来源: JAMA. 2023年329卷11期910-917页

The early postpartum period, 2 to 4 weeks after birth, may be a convenient time for intrauterine device (IUD) placement; the placement could then coincide with early postpartum or well-baby visits.

5057. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.

作者: Mazyar Shadman.
来源: JAMA. 2023年329卷11期918-932页

Chronic lymphocytic leukemia (CLL), defined by a minimum of 5 × 109/L monoclonal B cells in the blood, affects more than 200 000 people and is associated with approximately 4410 deaths in the US annually. CLL is associated with an immunocompromised state and an increased rate of complications from infections.

5058. Toward Personalizing Care: Assessing Heterogeneity of Treatment Effects in Randomized Trials.

作者: Issa J Dahabreh.;Dhruv S Kazi.
来源: JAMA. 2023年329卷13期1063-1065页

5059. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.

作者: Ewan C Goligher.;Patrick R Lawler.;Thomas P Jensen.;Victor Talisa.;Lindsay R Berry.;Elizabeth Lorenzi.;Bryan J McVerry.;Chung-Chou Ho Chang.;Eric Leifer.;Charlotte Bradbury.;Jeffrey Berger.;Beverly J Hunt.;Lana A Castellucci.;Lucy Z Kornblith.;Anthony C Gordon.;Colin McArthur.;Steven Webb.;Judith Hochman.;Matthew D Neal.;Ryan Zarychanski.;Scott Berry.;Derek C Angus.; .
来源: JAMA. 2023年329卷13期1066-1077页

Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making.

5060. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.

作者: Pierre Bouzat.;Jonathan Charbit.;Paer-Selim Abback.;Delphine Huet-Garrigue.;Nathalie Delhaye.;Marc Leone.;Guillaume Marcotte.;Jean-Stéphane David.;Albrice Levrat.;Karim Asehnoune.;Julien Pottecher.;Jacques Duranteau.;Elie Courvalin.;Anais Adolle.;Dimitri Sourd.;Jean-Luc Bosson.;Bruno Riou.;Tobias Gauss.;Jean-François Payen.; .
来源: JAMA. 2023年329卷16期1367-1375页

Optimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption.

结果排序

文献格式

出版时间

出版类型

出版语言